Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19029290 | 0.99 | HDAC6 (0.98) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL21352550 | 0.94 | HDAC6 (0.88) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL19029831 | 0.93 | HDAC6 (0.86) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL19029104 | 0.88 | HDAC6 (0.79) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL19029292 | 0.85 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21352551 | 0.84 | HDAC6 (0.73) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL21352481 | 0.83 | HDAC6 (0.71) | HDAC6NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL23677097 | 0.83 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19029584 | 0.83 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| Trifluoroacetic Acid SCHEMBL19029761 | 0.82 | HDAC6 (0.70) | HDAC6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602812-B | Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals | 坎塞拉有限公司 | 2021-11-02 | — | — | CN | claimed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | claimed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | claimed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | claimed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885NPC1 3040/4885RAB9A 2788/4885 |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885NPC1 3040/4885RAB9A 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.